Day 4 of the 25th annual International Symposium on Endovascular Therapy (ISET) is under way today at the Fontainebleau hotel in Miami Beach, Florida. More than 1,400 clinicians are here taking advantage of live case presentations, general educational sessions, and exhibits from 50 companies in the exhibit hall. The keynote address by Brian Keeley, president and CEO of Baptist Health South Florida, sparked discussion among attendees about how endovascular specialists will need to adjust their practice in the face of the Affordable Care Act. And important clinical topics at this meeting include critical limb ischemia and renal denervation, which presenter John Osborn, PhD, said could have implications not only for resistant hypertension but also for other diseases like diabetes and sleep apnea. Late-breaking trial results have been presented, such as those from Cordis, which announced its 2-year results from the STROLL trial that showed that freedom from clinically driven target lesion revascularization at 2 years with the S.M.A.R.T. stent system was 80.3%. Phase II results of the PEARL registry trial also showed that combination therapy can be successful at treating DVT.
The 5th Symposium on Clinical Interventional Oncology was held during the first 2 days of the meeting and included case-based reviews and discussion on developments in interventional oncology, such as encouraging results for the use of radiofrequency ablation for treatment of colorectal cancer. Results from a study on Y-90 radioembolization were also presented.
Yesterday, VDM editor in chief Frank Criado, MD, FACS, FSVM, spoke with endovascular pioneer Frank Veith, MD, about the history of and evolution in treatment for critical limb ischemia. Stay tuned to Vascular Disease Management’s multimedia center for publication of this exclusive video interview in the near future.
“Interventional medicine and endovascular therapy have become a huge universe that continues to expand at an ever-quickening pace,” said Dr. Criado of the conference. “Moving forward, our own imagination and costs will be the only possible limitations.”
Topics being presented today include pedal and radial access, central venous occlusions, endoleaks, EVAR and TEVAR, renal and visceral interventions, and drug-eluting balloons and stents. The conference wraps up tomorrow with information on drug elution, peripheral artery disease, chronic total occlusion, stroke therapy, and IVC filters.